Practice Changing Updates in the EGFR+ and KRAS+ NSCLC Space
Andreas Saltos, MD, discusses the current space for patients with non-small cell lung cancer harbording EGFR and KRAS mutations.
Key Takeaways From a Trial of Erlotinib/Binimetinib in EGFR+ or KRAS+ NSCLC
Andreas Saltos, MD, discusses the key discoveries from a phase 1/1B trial of erlotinib and binimetinib in EGFR- and KRAS-mutated non–small cell lung cancer.
Looking Forward in EGFR+ and KRAS+ NSCLC
Andreas Saltos, MD, discusses what he anticipates future research will examine regarding treatment options for EGFR and KRAS-mutated non-small cell lung cancer.
Reviewing Erlotinib/Binimetinib Combo in EGFR+ or KRAS+ NSCLC
Andreas Saltos, MD, discusses the key takeaways of the phase 1/1b clinical trial exploring the use of binimetinib plus erlotinib in patients with non–small cell lung cancer harboring either KRAS or EGFR mutations.
Binimetinib/Erlotinib Shows Tolerability in EGFR- or KRAS-Mutated NSCLC
Andreas Saltos, MD, discusses a phase 1 trial of binimetinib and erlotinib for patients with non–small cell lung cancer and EGFR or KRAS mutations.
2 Clarke Drive Cranbury, NJ 08512